> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Verrica NDA for Molluscum Topical
- URL: https://www.fdaweb.com/fda-oks-verrica-nda-for-molluscum-topical/
- Published: 2023-07-24T12:00:00.000Z
- Updated: 2026-09-14T18:45:51.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154940

FDA has approved a Verrica Pharmaceuticals NDA for Ycanth (cantharidin) topical solution for treating molluscum contagiosum (molluscum) in adult and pediatric patients. The company says molluscum is highly contagious and is commonly transmitted in households, schools, swimming pools and other extra-curricular settings. “Since molluscum spreads through skin-to-skin contact and the sharing of contaminated objects with its viral lesions, a topical treatment with precise administration is essential towards preventing further transmission,” it says.

Approval was based on data from two identical Phase 3 randomized, double-blind, multicenter clinical trials (CAMP-1 and CAMP-2) in patients two years of age and older diagnosed with molluscum, according to Verrica. “In both trials, a clinically and statistically significant number of patients treated with VP-102 \[cantharidin\] met the primary endpoint of complete clearance of all treatable molluscum lesions,” it says. “In CAMP-1, 46% of participants treated with VP-102 achieved complete clearance of molluscum lesions compared to 18% of participants in the vehicle group (p<0.0001); in CAMP-2, 54% of participants treated with VP-102 achieved complete clearance of molluscum lesions compared to 13% of participants in the vehicle group (p<0.0001).”